trending Market Intelligence /marketintelligence/en/news-insights/trending/KomskNs5Hw_nlCIwfHG88Q2 content esgSubNav
In This List

Bioblast Pharma regains compliance with Nasdaq listing rule

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Bioblast Pharma regains compliance with Nasdaq listing rule

Bioblast Pharma Ltd. regained compliance with a Nasdaq listing rule that requires the company to maintain a minimum bid price of $1 per share.

After 10 consecutive business days following the company's 1-for-5 reverse stock split on Sept. 25, the closing bid price for Bioblast's ordinary shares was $1 per share or greater, the company said in a filing.